Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Oliver, P. Sterba, Kelly Devine, B. Vonakis, S. Saini (2016)
Altered expression of chemoattractant receptor-homologous molecule expressed on T(H)2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria.The Journal of allergy and clinical immunology, 137 1
Jeffrey Harris, Christopher Cabanski, H. Scheerens, D. Samineni, Mary Bradley, C. Cochran, P. Staubach, M. Metz, G. Sussman, M. Maurer (2016)
A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.The Journal of allergy and clinical immunology, 138 6
M. Ghazanfar, C. Sand, S. Thomsen (2016)
Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patientsBritish Journal of Dermatology, 175
Marcus Maurer, S. Altrichter, M. Metz, Torsten Zuberbier, Martin Church, K. Bergmann (2018)
Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticariaJournal of the European Academy of Dermatology and Venereology, 32
Z. Vadasz, Y. Tal, M. Rotem, Vered Shichter-Confino, K. Mahlab-Guri, Y. Graif, A. Kessel, N. Agmon-Levin, R. Maoz-Segal, S. Kivity, Shira Benor, I. Lachover-Roth, Y. Zeldin, M. Stein, O. Toker, G. Hassoun, S. Bezalel-Rosenberg, E. Toubi, I. Asher, Z. Sthoeger (2017)
Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients.The journal of allergy and clinical immunology. In practice, 5 6
N. Bangsgaard, L. Skov, C. Zachariae (2017)
Treatment of Refractory Chronic Spontaneous Urticaria with Adalimumab.Acta dermato-venereologica, 97 4
A. Nyborg, A. Zacco, R. Ettinger, M. Borrok, Jie Zhu, Tom Martin, R. Woods, C. Kiefer, M. Bowen, E. Cohen, R. Herbst, Herren Wu, S. Coats (2015)
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cellsCellular and Molecular Immunology, 13
N. Kitsioulis, P. Xepapadaki, A. Roussaki-Schulze, N. Papadopoulos, E. Zafiriou (2017)
Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous UrticariaInternational Archives of Allergy and Immunology, 172
C. Dressler, S. Rosumeck, R. Werner, M. Magerl, M. Metz, M. Maurer, A. Nast, T. Zuberbier (2018)
Executive summary of the methods report for ‘The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update’Allergy, 73
F. Siebenhaar, F. Redegeld, S. Bischoff, B. Gibbs, M. Maurer (2017)
Mast Cells as Drivers of Disease and Therapeutic Targets.Trends in immunology, 39 2
T. Casale (2017)
Biologics and biomarkers for asthma, urticaria, and nasal polyposis.The Journal of allergy and clinical immunology, 139 5
Norbert Haas, B. Hermes, B. Henz (2001)
Adhesion molecules and cellular infiltrate: histology of urticaria.The journal of investigative dermatology. Symposium proceedings, 6 2
K. Altman, Christopher Chang (2013)
Pathogenic Intracellular and Autoimmune Mechanisms in Urticaria and AngioedemaClinical Reviews in Allergy & Immunology, 45
A. Kessel, Wissam Helou, E. Bamberger, E. Sabo, D. Nusem, Josef Panassof, E. Toubi (2010)
Elevated Serum Total IgE – A Potential Marker for Severe Chronic UrticariaInternational Archives of Allergy and Immunology, 153
G. Vena, M. Maurer, N. Cassano, T. Zuberbier (2017)
Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithmCurrent Opinion in Allergy and Clinical Immunology, 17
A. Navinés-Ferrer, E. Serrano-Candelas, G. Molina-Molina, Margarita Martín (2016)
IgE-Related Chronic Diseases and Anti-IgE-Based TreatmentsJournal of Immunology Research, 2016
A. Herman, L. Chinn, Shweta Kotwal, Elaine Murray, R. Zhao, M. Florero, A. Lin, A. Moein, R. Wang, Meire Bremer, S. Kokubu, A. Serone, E. Hanze, Anders Viberg, A. Morimoto, H. Winter, T. Katsumoto (2018)
Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase InhibitorClinical Pharmacology & Therapeutics, 103
M. Sánchez-Borges, A. Capriles-Hulet, F. Caballero-Fonseca, L. González-Aveledo (2017)
Justification for IgE as a therapeutic target in chronic spontaneous urticaria.European annals of allergy and clinical immunology, 49 4
S. Zheleznov, G. Urzhumtseva, N. Petrova, Zhanna Sarsaniia, N. Didkovskii, T. Dörr, T. Zuberbier (2018)
Gastritis Can Cause and Trigger Chronic Spontaneous Urticaria Independent of the Presence of Helicobacter pyloriInternational Archives of Allergy and Immunology, 175
M. Metz, T. Ohanyan, M. Church, M. Maurer (2014)
Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.Journal of dermatological science, 73 1
E. Kocatürk, M. Maurer, M. Metz, C. Grattan (2017)
Erratum to: Looking forward to new targeted treatments for chronic spontaneous urticariaClinical and Translational Allergy, 7
I. Harvima, F. Levi‐Schaffer, P. Dráber, Sheli Friedman, Iva Polakovičová, B. Gibbs, U. Blank, G. Nilsson, M. Maurer (2014)
Molecular targets on mast cells and basophils for novel therapies.The Journal of allergy and clinical immunology, 134 3
B. Gruber, B. Gruber, M. Baeza, M. Baeza, M. Marchese, M. Marchese, V. Agnello, V. Agnello, A. Kaplan, A. Kaplan (1988)
Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes.The Journal of investigative dermatology, 90 2
H. Yahara, Takahiro Satoh, C. Miyagishi, Hiroo Yokozeki (2010)
Increased expression of CRTH2 on eosinophils in allergic skin diseasesJournal of the European Academy of Dermatology and Venereology, 24
A. Kaplan, D. Ledford, M. Ashby, J. Canvin, J. Zazzali, E. Conner, J. Veith, Nikhil Kamath, P. Staubach, T. Jakob, R. Stirling, P. Kuna, W. Berger, M. Maurer, K. Rosen (2013)
Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.The Journal of allergy and clinical immunology, 132 1
S. Saini (2009)
Basophil responsiveness in chronic urticariaCurrent Allergy and Asthma Reports, 9
S. Buhner, I. Reese, F. Kuehl, H. Lochs, Torsten Zuberbier (2004)
Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeabilityAllergy, 59
L. Pennington, S. Tarchevskaya, D. Brigger, K. Sathiyamoorthy, M. Graham, K. Nadeau, A. Eggel, T. Jardetzky (2016)
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeNature Communications, 7
P. Minciullo, A. Cascio, G. Barberi, S. Gangemi (2014)
Urticaria and bacterial infections.Allergy and asthma proceedings, 35 4
S. Wenzel, L. Ford, D. Pearlman, S. Spector, L. Sher, F. Skobieranda, Lin Wang, S. Kirkesseli, R. Rocklin, Brian Bock, J. Hamilton, J. Ming, A. Radin, N. Stahl, G. Yancopoulos, N. Graham, G. Pirozzi (2013)
Dupilumab in persistent asthma with elevated eosinophil levels.The New England journal of medicine, 368 26
E. Bodar, Anna Simon, M. Visser, J. Meer (2009)
Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra).The Netherlands journal of medicine, 67 9
E. Imbalzano, M. Casciaro, S. Quartuccio, P. Minciullo, A. Cascio, G. Calapai, S. Gangemi (2016)
Association between urticaria and virus infections: A systematic review.Allergy and asthma proceedings, 37 1
C. Lenormand, D. Lipsker (2012)
Efficiency of Interleukin-1 Blockade in Refractory Delayed-Pressure UrticariaAnnals of Internal Medicine, 157
J. Arm, I. Bottoli, A. Skerjanec, D. Floch, A. Groenewegen, S. Maahs, C. Owen, I. Jones, P. Lowe (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjectsClinical and Experimental Allergy, 44
S. Saini, C. Bindslev‐Jensen, M. Maurer, J. Grob, E. Başkan, Mary Bradley, J. Canvin, Abdelkader Rahmaoui, P. Georgiou, O. Alpan, S. Spector, K. Rosen (2015)
Erratum: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study (Journal of Investigative Dermatology (2015) 135 (67-75)) DOI: 10.1038/jid.2014.306)Journal of Investigative Dermatology, 135
A. Combalia, Ricardo A. Losno, S. Prieto-González, J. Manuel Mascaró (2018)
Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic ApproachSkin Pharmacology and Physiology, 31
M. Maurer, K. Rosen, H. Hsieh, S. Saini, C. Grattan, A. Giménez-Arnau, S. Agarwal, R. Doyle, J. Canvin, A. Kaplan, T. Casale (2013)
Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.The New England journal of medicine, 368 10
O. Boyman, C. Kaegi, M. Akdiş, S. Bavbek, A. Bossios, Alexia Chatzipetrou, T. Eiwegger, D. Firinu, T. Harr, E. Knol, A. Matucci, Ó. Palomares, C. Schmidt‐Weber, H. Simon, U. Steiner, A. Vultaggio, C. Akdis, F. Spertini (2015)
EAACI IG Biologicals task force paper on the use of biologic agents in allergic disordersAllergy, 70
L. Wilson, Mark Eliason, K. Leiferman, C. Hull, D. Powell (2011)
Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors.Journal of the American Academy of Dermatology, 64 6
I. Pali-Schöll, R. Herzog, J. Wallmann, K. Szalai, R. Brunner, A. Lukschal, P. Karagiannis, S. Diesner, E. Jensen‐Jarolim (2010)
Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitizationClinical & Experimental Allergy, 40
Magerl (2008)
Urticaria – classification and strategies for diagnosis and treatmentCME Dermatol, 3
F. Sand, S. Thomsen (2015)
Off‐label use of TNF‐alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patientsDermatologic Therapy, 28
T. Zuberbier, M. Maurer (2007)
Urticaria: current opinions about etiology, diagnosis and therapy.Acta dermato-venereologica, 87 3
Beom-Sik Kim, A. Eggel, S. Tarchevskaya, M. Vogel, H. Prinz, T. Jardetzky (2012)
Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular InhibitorNature, 491
P. Staubach, K. Onnen, A. Vonend, M. Metz, F. Siebenhaar, I. Tschentscher, B. Opper, M. Magerl, R. Lüdtke, A. Kromminga, M. Maurer (2006)
Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled TrialDermatology, 212
M. Shirley (2017)
Dupilumab: First Global ApprovalDrugs, 77
P. Kolkhir, Galina Balakirski, Hans Merk, O. Olisova, Marcus Maurer (2016)
Chronic spontaneous urticaria and internal parasites – a systematic reviewAllergy, 71
G. Sussman, J. Hébert, C. Barron, J. Bian, Rose-Marie Caron-Guay, Stéphanie Laflamme, S. Stern (2014)
Real-life experiences with omalizumab for the treatment of chronic urticaria.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 112 2
M. Caproni, W. Volpi, B. Giomi, D. Torchia, E. Bianco, P. Fabbri (2006)
Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatmentBritish Journal of Dermatology, 155
R. Parslew, D. Pryce, J. Ashworth, P. Friedmann (2000)
Warfarin treatment of chronic idiopathic urticaria and angio‐oedemaClinical & Experimental Allergy, 30
Zuo-Tao Zhao, Chunmei Ji, Wen-jun Yu, Ling Meng, T. Hawro, Ji-Fu Wei, M. Maurer (2016)
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.The Journal of allergy and clinical immunology, 137 6
T. Zuberbier, D. Schadendorf, N. Haas, K. Hartmann, B. Henz (1997)
Enhanced P-selectin expression in chronic and dermographic urticaria.International archives of allergy and immunology, 114 1
M. Magerl, D. Terhorst, M. Metz, S. Altrichter, T. Zuberbier, M. Maurer, K. Bergmann (2018)
Benefit of mepolizumab treatment in a patient with chronic spontaneous urticariaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 16
R. Asero, M. Cugno, A. Tedeschi (2009)
Eosinophils in Chronic Urticaria: Supporting or Leading Actors?The World Allergy Organization Journal, 2
Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW URRENT PINION a b Emek Kocaturk € and Torsten Zuberbier Purpose of review Symptomatic management of chronic spontaneous urticaria (CSU) basically depends on second-generation H1 antihistamines and omalizumab. Omalizumab is a game changer in the management, but still there is a need for new targets and new biologics targeting new pathways in the treatment which will provide long- lasting remission, which will be given orally and which will be cheaper. This review will focus on new biologics that are underway of production or are already under use for different disorders but could be beneficial for the treatment of Chronic urticaria. Recent findings In this review, the treatment targets are classified according to the cells which are involved in the pathogenesis of CSU. Those are mast cells/basophils, B cells, T cells and eosinophils. The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab. Summary The ongoing clinical trials on new targets of
Current Opinion in Allergy & Clinical Immunology – Wolters Kluwer Health
Published: Oct 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.